Labopharm

What Labopharm does

Labopharm was an international specialty pharmaceutical company headquartered in Montreal, Canada, founded in 1990. The firm focused on optimizing the performance of existing drugs, an approach centered on drug reformulation and delivery innovation rather than novel-molecule discovery. The company was publicly traded on NASDAQ under the ticker DDSS prior to delisting, and at its operating scale employed between 51 and 100 people.

The company's business model centered on developing reformulated versions of established pharmaceuticals to improve attributes such as efficacy, safety, dosing convenience, or patient compliance, with an international commercial footprint. Specific product names, pipeline assets, and commercial partnerships are not documented in the available source material. A single recorded funding event — a $10 million financing from Hercules Capital in June 2005 — is the only capital-raise information present. Leadership included Mark D'Souza as President and CEO and Sylvain Guénette as CFO.

As of the available data, labopharm.com is listed for sale on the Spaceship.com domain marketplace and the company is recorded as closed in source data. This is consistent with the prior NASDAQ delisting and strongly suggests the company is no longer operational. The available input lacks granular product, revenue, and market data needed to reconstruct the company's full commercial trajectory prior to dissolution, and no successor or residual operating entity is documented.

Name

Labopharm

Website

https://labopharm.com

Company type

Private

Founded year

1990

Operating status

Closed

Headcount range

51–100 employees

Short description

Labopharm was a Montreal-based specialty pharmaceutical company founded in 1990 that reformulated existing drugs to improve their performance. Previously NASDAQ-listed under DDSS, the firm is now delisted and its domain is for sale.

Ownership category

akta.pro rank

Headquarters

HQ city

Montreal

HQ country

Canada

HQ region

North America

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Supply Chain, Operations, Personnel, Marketing or Sales

Core offering

Labopharm is an international specialty pharmaceutical company that develops and commercializes optimized formulations of existing drugs. Its core activity is applying proprietary drug delivery and formulation technology to create improved versions (such as once-daily or controlled-release formulations) of established pharmaceutical compounds for specialty therapeutic markets.

Differentiator

Problem solved

Functional benefit

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Recent moves4 records

Expansion highlights1 record

Broad incumbents

• Patheon (Thermo Fisher Scientific): Large-scale pharmaceutical development and manufacturing services provider with deep reformulation and drug-product capabilities; comparable on the technology/development side though structured as a services/CDMO.
• Endo International: Larger specialty pharmaceutical company with a portfolio built around reformulated and pain-focused products; comparable therapeutic and formulation orientation, but operates at materially greater scale.
• Catalent: Major drug delivery and formulation specialist that partners with pharma on reformulation, bioavailability, and controlled-release technologies; addresses the same drug-optimization problem from a CDMO angle.
• Impax Laboratories (now Amneal Pharmaceuticals): Specialty/generic pharmaceutical company with a significant reformulation and controlled-release product portfolio; comparable business model combining specialty pharma with generic and 505(b)(2) reformulation work.
• Mallinckrodt: Specialty pharmaceutical company with a portfolio oriented to reformulated, abuse-deterrent, and branded specialty products; comparable in segment positioning though at much larger scale.

Direct peers

• Biovail Corporation: Canadian specialty pharmaceutical company with a strong focus on drug delivery technologies and reformulation of existing molecules — closely mirrors Labopharm's 'optimizing the performance of existing drugs' positioning.
• Paladin Labs: Montreal-based specialty pharmaceutical company historically focused on acquiring or in-licensing specialty products; directly comparable in geography, scale, and reformulation/commercialization strategy, and historically the acquirer of Labopharm's commercial assets.
• Nuvo Research: Mississauga-based specialty pharma developing reformulated versions of existing drugs (notably topical diclofenac and Pennsaid); directly comparable niche strategy and Canadian life-sciences ecosystem.
• Valeant Pharmaceuticals (Bausch Health): Canadian-headquartered specialty pharma historically built around reformulating and commercializing existing drugs across multiple therapeutic categories; very similar strategic model and geographic base.

Regional players

• Jazz Pharmaceuticals: Specialty pharma focused on CNS and reformulated products, primarily U.S./European; comparable therapeutic and reformulation orientation but different primary geography than Montreal-anchored Labopharm.

Market position

Strengths2 records

Weaknesses3 records

Competitive moat2 records

Key risks4 records

Key highlights4 records

Customer concentration

• LinkedInlinkedin.com/company/labopharm

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Labopharm